Trial Profile
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Preliminary Results (n=23 ) assessing safety and efficacy of Durvalumab (Anti-PD-L1) & Lenalidomide in Refractory/Advanced Cutaneous T Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Jan 2023 Planned End Date changed from 8 Jun 2023 to 1 Jun 2026.
- 12 Jan 2023 Planned primary completion date changed from 8 Mar 2023 to 1 Jun 2025.